Form 4: ACTU COO Andrew Mazar Granted 105,000 Stock Options

Actuate Therapeutics' Chief Operating Officer, Andrew Paul Mazar, received a grant of 105,000 employee stock options with an exercise price of $2.49, vesting over four years.

Summary

• Andrew Paul Mazar, Chief Operating Officer of Actuate Therapeutics, Inc. (ACTU), was granted 105,000 employee stock options.
• The options have an exercise price of $2.49 per share.
• The grant date for these options was April 1, 2026.
• The options will begin vesting on April 1, 2027, with 25% vesting on that date.
• The remaining 75% will vest in equal monthly installments over the 36 months following the first anniversary of the grant date.
• The options have an expiration date of April 1, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as the grant of stock options aligns the Chief Operating Officer's long-term financial interests with those of shareholders, incentivizing performance.

Positives

• The grant of employee stock options aligns the Chief Operating Officer's long-term financial interests with those of shareholders, incentivizing performance and commitment to the company's success.

Negatives

• Potential future dilution for existing shareholders if all options are exercised, although this is a standard aspect of equity-based compensation.

Future Outlook

The vesting schedule for the stock options, extending over four years, indicates a long-term commitment from the Chief Operating Officer to Actuate Therapeutics' future performance and strategic objectives.

Industry Context

StockSavvy.ai notes that executive stock option grants are a common component of compensation packages across various industries, designed to align executive interests with long-term shareholder value. This grant is a routine disclosure for executive compensation.

Comparison to Industry Standards

• Executive stock option grants are a standard practice in the biotechnology and pharmaceutical sectors, similar to companies like Moderna or Pfizer, where long-term incentives are crucial for retaining key talent and driving innovation.
• The four-year vesting schedule is typical for executive equity awards, comparable to industry benchmarks aimed at fostering sustained performance and executive retention.
• The grant size of 105,000 options for a Chief Operating Officer at a company like Actuate Therapeutics appears consistent with compensation structures observed in similar-sized public companies within the life sciences industry, though specific comparisons would require detailed peer group analysis.

Stakeholder Impact

• Shareholders: Potential for increased management alignment with shareholder interests, but also potential future dilution if options are exercised.
• Employees: The grant to a key executive may signal stability and long-term vision within the company's leadership.

Next Steps

• The options will vest as to 25% on April 1, 2027.
• The remaining 75% will vest in equal monthly installments during the 36 months following April 1, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event, specifically an option grant, which does not provide sufficient new information to warrant a change in investment recommendation. It primarily serves to align management incentives with shareholder interests, a standard corporate practice.

Keywords

Actuate Therapeutics, ACTU, Andrew Paul Mazar, Chief Operating Officer, Stock Options, Employee Stock Option, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Vesting Schedule